XTL Biopharmaceuticals Ltd. (TLV:XTLB)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
4.100
-0.100 (-2.38%)
Jun 26, 2025, 3:13 PM IDT
-52.33%
Market Cap 34.37M
Revenue (ttm) 1.64M
Net Income (ttm) -3.74M
Shares Out 881.39M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,405,000
Average Volume 458,163
Open 4.300
Previous Close 4.200
Day's Range 3.900 - 4.300
52-Week Range 0.063 - 11.200
Beta 0.99
RSI 40.62
Earnings Date Aug 9, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 10
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.